Classification and sites of TB infection, by drug
| ETA n=8 {5} | INF n=12 {11} | ADA n=20 {11} | All anti-TNF n=40 {27} | |
|---|---|---|---|---|
| Pulmonary, n=15 (38% total) | ||||
| Lower respiratory tract | 4 {2} | 2 {2} | 6 {3} | 12 {7} |
| Pleural | – | 2 {2} | 1 {1} | 3 {3} |
| Total pulmonary | 4 {2} | 4 {4} | 7 {4} | 15 {10} |
| Extra-pulmonary (including disseminated), n=25 (62% total) | ||||
| Bone and joint | 1 {1} | – | – | 1 {1} |
| Gastrointestinal | – | 3 {3} | – | 3 {3} |
| Lymph node | 2 {2} | 2 {2} | 2 {2} | 6 {6} |
| Central nervous system | – | 1 {1} | 2 {1} | 3 {2} |
| Pharyngeal wall | – | – | 1 {1} | 1 {1} |
| Disseminated | 1 {0} | 2 {1} | 8 {3} | 11 {4} |
| Total extrapulmonary | 4 {3} | 8 {7} | 13 {7} | 25 {17} |
Numbers represent number of cases attributable to most recent drug {number of cases while "on drug"}.
ADA, adalimumab; ETA, etanercept; INF, infliximab; TB, tuberculosis; TNF, tumour necrosis factor.